Reuters logo
in a month
BRIEF-Trovagene announces submission of investigational NDA to initiate trial of PCM-075
June 27, 2017 / 12:27 PM / in a month

BRIEF-Trovagene announces submission of investigational NDA to initiate trial of PCM-075

1 Min Read

June 27 (Reuters) - Trovagene Inc

* Trovagene announces submission of investigational new drug application to initiate phase 1B/2 clinical trial of PCM-075 for acute myeloid leukemia

* Trovagene plans to initiate clinical trials of PCM-075 in AML

* Have IND and protocol for phase 1B/2 clinical trial submitted and under review by FDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below